Cure Forward Receives $15M in Series A Financing Round

Cure Forward, a privately held patent activation company, announced today that it has secured $15 million in a Series A financing. Apple Tree Partners, which is the sole investor in Cure Forward, officially launches the Company with this commitment.

The funds will be used to create a multisided technology platform for healthcare built around the science and technology of precision medicine. Cure Forward will harness molecular science to connect patients with relevant information, treatment options, and other patients with similar characteristics, making patient participation in precision healthcare possible.

Martin Naley, CEO of Cure Forward, stated:

“We believe there is an entirely new way for people to approach their disease. What Cure Forward will accomplish will be much like Airbnb and Kickstarter, technology platforms that connect people in new ways. We are using scientific information to bring together audiences that previously had no way of finding each other, and when they can, it will unleash enormous value and accelerate cures.”

Aaron Kantoff, Vice President of Apple Tree Partners and a Director at Cure Forward, added:

“Apple Tree Partners is dedicated to creating and building transformational healthcare companies. We are thrilled to have supported Cure Forward throughout its journey from a promising concept to a groundbreaking technology platform with a broad range of possibilities, all of which have the potential to improve the lives of so many patients. The world of precision medicine is evolving rapidly and we believe Cure Forward addresses a profound need to connect patients with therapies tailored specifically to their disease. Empowering patients with this access will further accelerate the innovative research needed to advance toward cures and, most importantly, save lives.”

Cure Forward is currently in a private beta and will launch in September of 2015.